Viruses that possess class I fusion proteins require proteolytic activation by host cell proteases to mediate 19 fusion with the host cell membrane, which is a crucial step in infection. The mammalian SPINT2 gene 20 encodes a protease inhibitor that inhibits a range of trypsin-like serine proteases, including those known 21 to act on class I fusion proteins. Here we show the protease inhibitor SPINT2 restricts cleavage-activation 22 with high efficacy, for a range of influenza viruses and for human metapneumovirus, and for cleavage via 23 a series of functionally-relevant proteases: namely trypsin, recombinant matriptase, kallikrein-related 24 2 peptidases (KLK) 5 & 12, human-airway trypsin-like protease (HAT) and plasmin. SPINT2 inhibitor 25 treatment resulted in the cleavage and fusion inhibition of full-length influenza A/Ca/04/09 (H1N1) HA, 26 A/Aichi/68 (H3N2) HA and A/Shanghai/2/2013 (H7N9) HA when activated by trypsin, recombinant 27 matriptase or KLK5. For HMPV, SPINT2 inhibitor was also able to block cleavage of F by trypsin, KLK5 and 28 matriptase. We also demonstrate that SPINT2 inhibitor was able to reduce viral growth of influenza 29 A/Ca/04/09 H1N1 and A/X31 H3N2 in cell culture by inhibiting matriptase or TMPRSS2. Moreover, 30 inhibition efficacy did not differ whether SPINT2 was added at the time of infection or 24 hours post-31 infection. Our data suggest that the SPINT2 inhibitor has a strong potential to serve as a novel antiviral 32 therapy with a broad spectrum. 33
Introduction 46
Influenza-like illnesses (ILIs) represent a significant burden on public health and can be caused by a range 47 of respiratory viruses in addition to influenza virus itself (1). An ongoing goal of anti-viral drug discovery 48 3 is to develop broadly-acting therapeutics that can be used in the absence of definitive diagnosis, such as 49 in the case of ILIs. For such strategies to succeed, drug targets that are shared across virus families need 50 to be identified. 51
One common cause of ILI are influenza A viruses, including H1N1 and H3N2, that cross species barriers 52 from their natural avian hosts and infect humans (2, 3) . Novel emerging viruses such as H7N9 that has 53 caused hundreds of deaths since its appearance in China in 2013 pose an additional concern (4). The World 54
Health Organization (WHO) estimates that each year about 1 billion suffer from flu infections, 3 to 5 55 million people worldwide are hospitalized with severe illness and approximated 290,000 to 650,000 56 people die from the disease (5). Mortality rates dramatically rise during influenza pandemics as observed 57 with the Spanish flu of 1918, the Asian pandemic of 1957 and the Hong Kong pandemic of 1968 (3, 6) . 58
Vaccinations can provide an effective protection against seasonal and pandemic outbreaks but provide 59 limited or no protection when viruses evolve and/or acquire mutations resulting in antigenically distinct 60 viruses. This antigenic drift or shift requires that new vaccines be produced quickly and in vast amounts 61 which can be problematic especially during pandemics. In addition to vaccines, several antiviral therapies 62 have been applied to treat influenza A infections such as adamantanes acting as M2 ion channel blockers 63 (amantadine, rimantadine) and neuraminidase inhibitors which block the cleavage of sialic acid in newly 64 formed virions (oseltamivir, zanamivir) (7). However, several influenza subtypes including the most 65 common H1N1 and H3N2 have emerged globally that are resistant against adamantanes and similar 66 observations were made with respect to oseltamivir (7) . 67
Another common cause of ILI is pneumo-and paramyxoviruses, including human metapneumovirus 68 (HMPV), respiratory syncytial virus, and parainfluenza viruses. Clinical presentation of these viruses 69 resembles many of the symptoms of influenza and they cause significant morbidity and mortality as well 70 as a large economic burden (8, 9) . HMPV is ubiquitous, with nearly everyone infected by the age of 5 and 71 reinfection is common throughout life impacting children, elderly and immunocompromised individuals 72 4 (10-12). While HMPV is a common cause of ILI, there are currently no approved vaccines or antiviral 73 therapeutics. Further research is needed to establish targets for intervention and factors required for 74 infection need to be examined in more detail. 75 Some influenza viruses and HMPV appear to share common activating proteases. The influenza fusion 76 protein hemagglutinin (HA) is synthesized as a precursor that needs to be cleaved by host cell proteases 77 to exert its fusogenic activity (13, 14) . Cleavage separates the precursor HA0 into HA1 and HA2 which 78 remain associated via disulfide bonds and leads to exposure of the fusion peptide at the N-terminus of 79 HA2 (13, 14) . Low pathogenicity avian influenza (LPAI) usually possess a monobasic cleavage site which 80 consists of 1 -2 non-consecutive basic amino acids and which is generally cleaved by trypsin-like serine 81 proteases such trypsin, and members of the type II transmembrane serine proteases (TTSP) including 82 TMPRSS2, TMPRSS4, HAT (TMPRSS11D) and matriptase (13) (14) (15) . In addition, some other proteases such 83 as KLK5 and KLK 12 have been implicated in influenza pathogenicity (16). In humans these proteases are 84 localized in the respiratory tract and therefore influenza infections are usually confined to this tissue. In 85 contrast, highly pathogenic avian influenza (HPAI) viruses are defined by a polybasic cleavage site which 86 consists of 6 -7 basic residues allowing them to be activated by members of the proprotein convertase 87 (PC) family such as furin and PC6 (17). These proteases are not confined to a specific tissue and 88 dramatically increase the risk of a systemic infection. 89
Similar to influenza HA, HMPV requires the fusion protein (F) to be proteolytically processed at a single 90 basic residue to generate the active, metastable form. Without this cleavage process, the F protein is 91 unable to mediate viral entry into the target cell. However, to date, only trypsin and TMPRSS2 have been 92 shown to effectively cleave HMPV F and other proteases have yet to be identified (18, 19) . 93
In addition, other respiratory viruses have been reported to utilize similar proteases for activation, 94
including SARS and MERS, demonstrating that targeting these proteases would inhibit multiple respiratory 95 pathogens (20) . The fact that proteolytic activation is such a crucial step for several respiratory viruses 96 5 that predominately require a specific class of proteases makes these proteases a viable target for the 97 development of novel antiviral therapies (21). Earlier studies described the administration of the serine 98 protease inhibitor aprotinin to inhibit influenza replication and demonstrated that aprotinin successfully 99 inhibited IAV activation and replication (22). However, when targeting host specific factors there are 100 potential off target effects, and therefore the potential side effects of targeting host proteases requires 101 further investigation. Hamilton et al. reported that the hepatocyte growth activator inhibitor 2 (HAI-2) 102 effectively inhibited trypsin-mediated cleavage of H1N1 and H3N2 in vitro and in vivo (23). HAI-2 is 103 encoded by the SPINT2 gene and hereafter we will also refer to the protein as SPINT2. SPINT2 is plasma 104 membrane-localized serine protease inhibitor that is found in various tissues including the respiratory 105 tract (24). Recent reports associated the physiological role of SPINT2 with the inhibition of serine-type 106 proteases such as matriptase and plasmin and that deregulation of SPINT2 inhibition is suggested to play 107 a role in cancer development and progression (25) (26) (27) . SPINT2 possesses two kunitz-type inhibitor 108 domains that are exposed to the extracellular space and which are believed to facilitate a potent inhibition 109 of target proteases. Wu et al. recently described that the kunitz-type domain 1 of SPINT2 is responsible 110 for matriptase inhibition (25). 111 A previous study from our lab described the effective inhibition of trypsin by SPINT2 resulting in 112 dramatically reduced cleavage of influenza A HA and subsequent reduced viral growth in cell culture and 113 mouse studies (23). Here, we report that purified SPINT2 protein inhibits several human host proteases 114 such as matriptase and TMPRSS2 that are relevant for the activation of significant influenza viruses 115 currently circulating and causing disease outbreaks. We also tested the potential of SPINT2 to inhibit the 116 activation of the fusion protein (F) from human metapneumovirus (HMPV), a member of the pneumovirus 117 family. We confirm the original findings that HMPV F is proteolytically processed by trypsin and TMPRSS2. 118
In addition, we found that HAT, KLK5 and matriptase were able to cleave F, but KLK12 could not. Our 119 results show that SPINT2 can inhibit the activation of proteases that are responsible for the activation of 120 6 influenza H1N1, H3N2 and H7N9 HA as well as HMPV F. In a cell culture model, we demonstrate that viral 121 loads are significantly reduced in the presence of SPINT2 when infections were conducted with 122 A/Ca/04/09 and A/X31. Moreover, the application of SPINT2 24 hours post infection inhibited the 123 activation of influenza A viruses with the same efficacy as when SPINT2 was added to cell culture medium 124 at the time of infection. Thus, SPINT2 exhibits the potential to serve as a novel and efficient antiviral 125 therapeutic to relieve patients from influenza A, human metapneumovirus, SARS and potentially other 126 respiratory viruses that require these host factors for entry. 127
Results 128
SPINT2 inhibits recombinant human respiratory tract proteases that cleave HA cleavage site peptide 129 mimics 130
We previously tested the ability of SPINT2 to inhibit proteases shown to cleave HAs from seasonal and 131 pandemic influenza A strains that infected humans by using a fluorogenic peptide cleavage assay that 132 utilizes fluorogenic peptides mimicking the HA cleavage site (28, 29) . We found that certain HA subtypes 133 such as H1, H2 and H3 are cleaved by a wide variety of human respiratory proteases while others such H5, 134 H7 and H9 displayed more variability in cleavage by proteases and seemed less well adapted to proteases 135 present in the human respiratory tract (29). Here, we extended our previous study and tested a peptide 136 mimicking the cleavage site of the pneumovirus fusion protein of HMPV F with a variety of proteases for 137 their ability to cleave the peptide mimic ( Figure 1) (19, 30) . When we tested cleavage of a peptide 138 mimicking the HMPV F cleavage site by trypsin, matriptase, KLK5, KLK12, HAT and plasmin we found that 139 all proteases except KLK12 were able to proteolytically cleave the peptide (Figure 1 ). However, the Vmax 140 values for matriptase (9.24 nM), KLK5 (5.8 nM) and HAT (2.99 nM) were very low compared to trypsin 141 (135.2) suggesting that the three proteases have a lower affinity interaction and processivity for HMPV F. 142
Next, trypsin, matriptase and KLK5 were selected for the SPINT2 inhibition assays as described below. 143 7 For the SPINT2 inhibition assays, trypsin which typically resides in the intestinal tract and expresses a very 144 broad activity towards different HA subtypes and HMPV F served as a control (31). We measured the Vmax 145 values for each protease/peptide combination in the presence of different SPINT2 concentrations and 146 plotted the obtained Vmax values against the SPINT2 concentrations on a logarithmic scale 147 ( Supplementary Figure 1) . Using Prism7 software, we then determined the IC50 that reflects at which 148 concentration the Vmax of the respective reaction is inhibited by half. SPINT2 cleavage inhibition of a 149 representative H1N1 cleavage site by trypsin results in an IC50 value of 70.6 nM (Table 1A) while the 150 inhibition efficacy of SPINT2 towards matriptase, HAT, KLK5 and KLK12 ranged from 11 nM to 25 nM (Table  151 1A). However, inhibition was much less efficient for plasmin compared with trypsin (122 nM). We 152 observed a similar trend when testing peptides mimicking the H3N2 and H7N9 HA cleavage sites using 153 trypsin, HAT, KLK5, plasmin and trypsin, matriptase, plasmin, respectively (Table 1A) . With the exception 154 of plasmin, we found that human respiratory tract proteases are inhibited with a higher efficacy compared 155 to trypsin. We expanded our analysis to peptides mimicking HA cleavage sites of H2N2, H5N1 (LPAI and 156 HPAI), H6N1 and H9N2 that all reflected the results described above (Table 1A) . Only cleavage inhibition 157 of H6N1 HA by KLK5 did not significantly differ from the observation made with trypsin (Table 1A ). 158
When we tested inhibition of HMPV cleavage by trypsin, matriptase and KLK5. SPINT2 showed a very high 159
inhibition efficacy for all three tested proteases with measured IC50s for trypsin, matriptase and KLK5 of 160 0.04 nM, 0.0003 nM and 0.95 nM, respectively (Table 1B) .Compared to the IC50 values observed with the 161 peptides mimicking influenza HA cleavage site motifs the IC50 values for the HMPV F peptide were very 162 low. 163
Cleavage of distinct full-length HA subtypes is efficiently inhibited by SPINT 164
Cleavage of peptides mimicking a HA cleavage site does not always reflect the in vivo situation and 165 requires validation by expressing the full-length HA protein in a cell culture model to test cleavage and 166 cleavage inhibition of the respective protease (29). However, before conducting these experiments we 167 8 wanted to ensure that SPINT2 does not have a cytotoxic effect on cells. Therefore, 293T cells were 168 incubated with various concentrations of SPINT2 over a time period of 24 hours. PBS and 500µM H2O2 169 served as cytotoxic negative and positive controls respectively. We did not observe any cytotoxicity with 170 any of the tested SPINT2 concentrations ( Figure 2) . 171
To test SPINT2-mediated cleavage inhibition of full-length HA we expressed the HAs of A/Ca/04/09 172 (H1N1), A/x31 (H3N2) and A/Shanghai/2/2013 (H7N9) in 293T cells and added recombinant matriptase or 173 KLK5 protease that were pre-incubated with 10nM or 500nM SPINT2. Trypsin and the respective protease 174 without SPINT2 incubation were used as controls. Cleavage of HA0 was analyzed via Western Blot and the 175 signal intensities of the HA1 bands were quantified using the control sample without SPINT2 incubation as 176 a reference point ( Figure 3A and 3B-D). Trypsin cleaved all tested HA proteins with very high efficiency 177
that was not observed with matriptase or KLK5 ( Figure 3B -D). However, H1N1 HA was cleaved by 178 matriptase and KLK5 to a similar extent without and with 10nM SPINT2. 500nM SPINT2 led to a cleavage 179 reduction of about 70% and 50% for matriptase and KLK5, respectively ( Figure 3A and 3B ). KLK5-mediated 180 cleavage of H3N2 HA was reduced by about 10% when KLK5 was pre-incubated with 10nM SPINT2 and by 181 about 60% when 500nM SPINT2 was used ( Figure 3A and 3C ). When we tested the cleavage inhibition of 182 matriptase with H7N9 HA as a substrate we found that 10nM and 500nM SPINT reduced the cleavage to 183 40% and 10% cleavage respectively compared to the control. ( Figure 3A and 3D). In contrast, 10nM SPINT2 184 had no effect on KLK5-mediated cleavage of H7N9 HA while 500nM reduced cleavage by approximately 185 70% ( Figure 3A and 3D) . 186
Next, we examined which proteases in addition to trypsin and TMPRSS2 were able to cleave HMPV F. First, 187 we co-transfected the full length TMPRSS2, HAT and matriptase with HMPV F in VERO cells. The F protein 188 was then radioactively labeled with 35 S methionine and cleavage was examined by quantifying the F0 full 189 length protein and the F1 cleavage product. We found that TMPRSS2 and HAT were able to efficiently 190 cleave HMPV F while matriptase decreased the expression of F, though it is not clear if this was due to 191 9 general degradation of protein or lower initial expression. However, matriptase demonstrated potential 192 low-level cleavage when co-transfected ( Figure 4A and B). We then examined cleavage by the exogenous 193 proteases KLK5, KLK12 and matriptase. Compared with the trypsin control, KLK5 and matriptase were able 194 to cleavage HMPV F, while KLK12 was not ( Figure 4C and D) . In agreement with the peptide assay, cleavage 195 of HMPV F by KLK5 and matriptase was less efficient than trypsin and both peptide and full length protein 196 assays demonstrate that KLK12 does not cleave. This also serves as confirmation that matriptase likely 197 cleaves HMPV F, but co-expression with matriptase may alter protein synthesis, stability or turnover if co-198 expressed during synthesis and transport to the cell surface. Next, we tested SPINT2 inhibition of 199 exogenous proteases trypsin, KLK5 and matriptase. We pre-incubated SPINT2 with each protease and 200 added it to VERO cells expressing HMPV F and analyzed cleavage product formation. SPINT2 pre-201 incubation minimally affected cleavage at 10nm but 500nm resulted in inhibition of trypsin, KLK5 and 202 matriptase cleavage of HMPV, similar to our findings for HA ( Figure 4E and F). 203
We also tested whether cleavage inhibition by SPINT2 resulted in the inhibition of cell fusion. As described 204 above, matriptase and KLK5 were pre-incubated with 10nM and 500nM SPINT2 and subsequently added 205 to VERO cells expressing A/Ca/04/09 (H1N1) HA or A/Shanghai/2/2013 (H7N9) HA. Cells were then briefly 206 exposed to a low pH buffer to induce fusion and subsequently analyzed using an immune fluorescence 207 assay. When matriptase and KLK5 were tested with 10nM SPINT2 and incubated with VERO cells 208 expressing H1N1 HA we still observed syncytia formation ( Figure 5A ). However, 500mM SPINT2 resulted 209 in the abrogation of syncytia formation triggered by cleavage of the respective HA by matriptase and KLK5. 210
We made the same observation when we tested KLK5 and H7N9 HA ( Figure 5B ). Matriptase-mediated 211 H7N9 HA syncytia formation was inhibited by the addition of 10nM SPINT2 ( Figure 5B ). 212
SPINT2 reduces viral growth in cell culture 213
To understand whether SPINT2 was able to inhibit or reduce the growth of live virus in a cell culture model 214 over the course of 24 hours we transfected cells with human TMPRSS2 and human matriptase, two major 215 10 proteases that have been shown to be responsible for the activation of distinct influenza A subtype 216 viruses. TMPRSS2 is essential for H1N1 virus propagation in mice and plays a major role in the activation 217 of H7N9 and H9N2 viruses (32-34) . Matriptase cleaves H1N1 HA in a sub-type specific manner, is involved 218 in the in vivo cleavage of H9N2 HA and our results described above suggest a role for matriptase in the 219 activation of H7N9 (16, 34) . At 18 hours post transfection we infected MDCK cells with A/Ca/04/09 (H1N1) 220 at a MOI of 0.1 and subsequently added SPINT2 protein at different concentrations. Non-transfected cells 221 served as a control and exogenous trypsin was added to facilitate viral propagation. SPINT2 initially 222 mitigated trypsin-mediated growth of H1N1 at a concentration of 50nM and the extent of inhibition 223 slightly increased with higher concentrations ( Figure 6A , Table 2A ). The highest tested SPINT2 224 concentration of 500nM reduced viral growth by about 1 log ( Figure 6A , Table 2A ). We observed a similar 225 pattern with cells transfected with human matriptase ( Figure 6B , Table 2A ). Growth inhibition started at 226 a SPINT2 concentration of 50nM and with the application of 500nM growth was reduced by approximately 227 1.5 logs ( Figure 6B , Table 2A ). When we infected cells expressing TMPRSS2 with H1N1 and added SPINT2, 228 viral growth was significantly reduced at a concentration of 150nM. Addition of 500nM SPINT2 led to a 229 reduction of viral growth of about 1.5 logs ( Figure 6C , Table 2A ). We also tested whether SPINT2 could 230 reduce the growth of a H3N2 virus because it is major circulating seasonal influenza subtype. However, 231 TMPRSS2 and matriptase do not seem to activate H3N2 viruses (16, 35) . Hence, trypsin and SPINT2 were 232 added to the growth medium of cells infected with A/X31 H3N2. Compared to control cells without added 233 inhibitor SPINT2 significantly inhibited trypsin-mediated H3N2 growth at a concentration of 50nM ( Figure  234 6D, Table 2A ). At the highest SPINT2 concentration of 500nM viral growth was reduced by about 1 log 235 ( Figure 6D) . 236 Antiviral therapies are often applied when patients already show signs of disease. Therefore, we tested if 237 SPINT2 was able to reduce viral growth when added to cells 24 hours after the initial infection. Cells were 238 infected with 0.1 MOI of A/Ca/04/09 (H1N1) and trypsin was added to promote viral growth. At the time 239 11 of infection, we also added 500nM SPINT2 to one sample. A second sample received 500nM SPINT2 24 240 hours post infection. Growth supernatants were harvested 24 hours later, and viral growth was analyzed. 241
We found that viral growth was reduced by 1 log regardless whether SPINT2 was added at the time of 242 infection or 24 hours later (Figure 7 , Table 2B ). 243
Discussion 244
Influenza A has caused four pandemics since the early 20 th century and infects millions of people each 245
year as seasonal flu resulting in up to 690,000 deaths annually (5). Vaccination efforts have proven to be 246 challenging due to the antigenic drift of the virus and emerging resistance phenotypes (36). Moreover, 247 the efficacy of vaccines seems to be significantly reduced in certain high-risk groups (37). Prevalent 248 antiviral therapies to treat influenza A-infected patients such as adamantanes and neuraminidase 249 inhibitors target viral proteins but there is increasing number of reports about circulating influenza A 250 subtypes that are resistant to these treatments (7) . In this study we focused on a novel approach that uses 251 antiviral therapies targeting host factors rather than viral proteins offering a more broad and potentially 252 more effective therapeutic approach (21). We demonstrate that SPINT2, a potent inhibitor of serine-type 253 proteases, is able to significantly inhibit cleavage of HA, impair the fusion of cells and hence, reduce viral 254 growth in vivo. 255 SPINT2 demonstrates greater advantage over other inhibitors of host proteases such as e.g. aprotinin that 256 was shown to be an effective antiviral but also seemed to be specific only for a subset of proteases (22). 257
Our peptide assay suggests that SPINT2 has a wide variety of host protease specificity. With the exception 258 of plasmin, all the tested proteases in combination with peptides mimicking the cleavage site of different 259 HA subtypes expressed IC50 values in the nanomolar range. Interestingly, the IC50 values obtained for 260 cleavage inhibition of HMPV F were substantially lower, in the picomolar range. This suggests that the 261 HMPV cleavage may be more selectively inhibited by SPINT2. However, the western blot data showed 262 that addition of the lowest concentration (10 nM) of SPINT2 did not result in cleavage inhibition of HMPV 12 F by the tested proteases. Differences in sensitivity of SPINT2 between influenza HA and HMPV require 264 further investigation. 265 SPINT2 poses several potential advantages over other inhibitors that target host proteases. Cell culture 266 studies showed that, for example, matriptase-mediated H7N9 HA cleavage was efficiently inhibited at a 267 concentration of 10nM SPINT2. In contrast, the substrate range for aprotinin, a serine protease inhibitor 268 shown to reduce influenza A infections by targeting host proteases, seemed to be more limited (22). Other 269 synthetic and peptide-like molecules designed to inhibit very specific serine proteases such as TMPRSS2, 270 TMPRSS4 and TMPRSS11D (HAT) were only tested with those proteases and their potential to inhibit other 271 proteases relevant for influenza A activation remains unclear (38) (39) (40) . However, when we tested the 272 potential of SPINT2 to inhibit viral replication in a cell culture model we were only able to achieve growth 273 reductions of approximately 1 -1.5 logs after 48 hours with a concentration of 500nM SPINT2. One 274 potential explanation is that 500nM SPINT2 was unable to saturate the proteases present in the individual 275 experiments and was not sufficient to prevent viral growth. In addition, the continuous overexpression of 276 matriptase and TMPRSS2 may have produced an artificially high quantity of protein that exceeded the 277 inhibitory capacities of SPINT2. This problem could be solved either by using higher concentration of 278 SPINT2 or by optimizing its inhibitory properties. SPINT2 did not express any cytotoxic effects up to a 279 concentration of 10mM. In comparison with other studies, the SPINT2 concentration we used here were 280 in the nanomolar range while other published inhibitors require micromolar concentrations (38) (39) (40) . 281
However, we believe that future research will allow to fully exploit the potential of SPINT2 as a broad-282 spectrum antiviral therapy. Wu et al., recently described that the Kunitz domain I of SPINT2 is responsible 283 for the inhibition of matriptase (25). In future studies we will explore whether the inhibitory capabilities 284 of SPINT2 can be condensed into small peptides that may improve its efficacy. Its ability to inhibit a broad 285 range of serine protease that are involved in the activation of influenza A suggest that a SPINT2 based 286 antiviral therapy could be efficient against other pathogens too. TMPRSS2, for example, does not only 287 13 play a major role in the pathogenesis of H1N1 but is also required for the activation of SARS (Severe Acute 288 Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) coronaviruses and HMPV (41, 42) . 289
Currently, treatment options for these viruses are very limited and therefore SPINT2 could become a 290 viable option if its potential as an antiviral therapeutic can be fully exploited. 291 (HyClone) supplemented with 10% FBS (Sigma). The plasmid encoding A/Ca/04/09 (H1N1) HA was 297 generated as described (16). The plasmid encoding for HMPV F S175H434 was generated as described (43) . 298
Materials and Methods
The plasmids encoding for A/Shanghai/2/2013 (H7N9) HA, human TMPRSS2 and human matriptase were 299 purchased from Sino Biological Inc. The plasmid encoding for A/Aichi/2/68 (H3N2) HA was generously 300 donated by David Steinhauer. A/Ca/04/09 and A/X31 viruses were propagated in eggs. All recombinant 301 proteases were purchased as described (29). 302
Expression and purification of SPINT2 303
SPINT2 was expressed and purified as described with minor modification (23). In brief, E. coli RIL (DE3) 304 arctic express cells (Agilent) were transformed with SPINT2-pSUMO. Cells were then grown in 0.5 L Luria 305
Broth containing 50 µg/ml kanamycin at 37°C. At OD 0.5-0.6 cells were chilled on ice and protein 306 expression was induced with 0.2 mM IPTG. Cells were then grown over night at 16°C. Cells were harvested 307 and protein was purified as previously described (23). SPINT2 protein was eluted by a 1-hour incubation 308 with ULP1-6xHis. Glycerol was added to the eluted SPINT2 protein to a final concentration of 20% and 309 protein aliquots were stored at -80°C. Protein concentration was determined by analyzing different 310 dilutions of SPINT2 on an SDS-PAGE gel along with 5 defined concentrations of BSA between 100 ng and 311 14 1 µg. The gel was then stained with Coomassie, scanned with ChemiDoc Imaging system (Bio-Rad) and 312 bands were quantified using Image Lab software (Bio-Rad). Concentrations of the SPINT2 dilutions were 313 determined based on the BSA concentrations and the final SPINT2 concentration was calculated based on 314 the average of the SPINT2 different dilutions. 315
Peptide Assays 316
Peptide assays were carried out as described (29) . The sequence of the HMPV F peptide mimicking the 317 HMPV F cleavage site used in this assay is ENPRQSRFVL including the same N-and C-terminal modifications 318 as described for the HA peptides (29). The Vmax was calculated by graphing each replicate in Microsoft 319
Excel and determining the slope of the reaction for every concentration (0 nM, 1 nM, 5 nM, 10 nM, 25 320 nM, 50 nM, 75 nM, 150 nM, 300 nM and 500 nM). The Vmax values were then plotted in the GraphPad 321
Prism 7 software against the log10 of the SPINT2 concentration to produce a negative sigmoidal graph 322 from which the IC50, or the concentration of SPINT2 at which the Vmax is inhibited by half, could be 323 extrapolated for each peptide protease mixture. Since the x-axis was the log10 of the SPINT2 324 concentration, the inverse log was then taken for each number to calculate the IC50 in nM. 325
Cytotoxicity assay 326
The cytotoxicity assay was performed with a cell counting kit-8 (Dojindo Molecular Technologies) 327 according to the manufacturer's instructions. In brief, approx. 2 x 10 3 293T cells were seeded per well of 328 a 96-well plate and grown over night. SPINT2 was added at the indicated concentrations. DMEM and 500 329 µM H2O2 were used as a control. 24 hours later 10 µl CKK-8 solution were added to each well and 330 incubated for 1 hour. Absorbance at 450 nm was measured using a SPARK microplate reader (Tecan). Per 331 sample and treatment three technical replicates were used and the average was counted as one biological 332 replicate. Experiment was conducted three times. 333
Metabolic protein labeling and immunoprecipitation of HMPV fusion protein 334 15 VERO cells were transfected with 2ug of pDNA using Lipofectamine and plus reagent (Invitrogen) in opti-335 mem (Gibco) according to the manufacturers protocol. The following day, cells were washed with PBS and 336 starved in cysteine/methionine deficient media for 45 min and radiolabeled with 50uC/mL S35-337 cysteine/methionine for 4 hours. Cells were lysed in RIPA lysis buffer and processed as described 338 previously (19) and the fusion protein of HMPV was immunoprecipitated using anti-HMPV F 54G10 339 monoclonal antibody (John Williams, U. Pitt). Samples were run on a 15% SDS-PAGE and visualized using 340 the typhoon imaging system. Band densitometry was conducted using ImageQuant software (GE). 341
SPINT2 cleavage inhibition by Western blot and cell-cell fusion assay 342
Experiments were performed as previously described with minor modifications (23). Treatment with 343 trypsin, recombinant matriptase and KLK5 were conducted as described (16, 44) . For western blot analysis 344
293T cells were transfected with Turbofect (Invitrogen) according to manufacturer's instructions. Cell-cell 345 fusion assays were conducted with Vero cells that were transfected with Lipofectamine according to the 346 manufacturer's instructions. Antibodies to detect A/Ca/04/09 (H1N1) HA (NR28666), A/Aichi/2/68 (H3N2) 347 HA (NR3118) and A/Shanghai/2/2013 (H7N9) HA (NR48765) were obtained from the Biodefense and 348
Emerging Infections Research Resources Repository. Respective secondary antibodies had an Alexa488 349 tag (Invitrogen). Western blot membranes were scanned using a ChemiDoc imaging system (Bio-Rad). For 350 quantification the pixel intensity of the individual HA1 bands was measured using ImageJ software and 351 cleavage efficiencies were calculated by the following equation: HA1 10 nM or 500 nM SPINT2/HA1 0nM 352 SPINT2 x 100%. Cell-cell fusion assays were carried out as described (16). 353
Inhibition of viral infection in cell culture 354
MDCK cells were seeded to a confluency of about 70% in 6-well plates. One plate each was then 355 transformed with a plasmid allowing for the expression of human matriptase or human TMPRSS2. One 356 plate was transformed with empty vector. 18 hours post transfection cells were infected with the 357 respective egg-grown virus at a MOI of approx. 0.1. Different SPINT2 concentrations were added as 358 16 indicated. 0.8 nM trypsin was added to the cells transformed with the empty vector. 48 hours post 359 infection supernatants were collected, centrifuged and stored at -80°C. Viral titers were determined using 360 an immune-plaque assay as described (45). 361 to express for ~ 18hours. Cells were then metabolically starved of cysteine and methionine followed by 522 radioactive S35 labeling of protein for 4 hours in the presence of TPCK-trypsin or specified protease. 523 SPINT2 treated proteases were incubated at room temperature for 10 minutes and placed onto cells for 524 4 hours. Radioactive gels were quantified using ImageQuant software with percent cleavage equal 525 to �� 1 0 + 1 � 100�. A and B) Co-transfected proteases TMPRSS2, HAT and matriptase are able to cleave 526 23 HMPV F while C and D) exogenous proteases KLK5 and matriptase but not KLK12 are able to cleave HMPV 527 F. E and F) SPINT2 prevented cleavage of HMPV F by trypsin, KLK5 and matriptase at nm concentrations 528 demonstrated by the loss of the F1 cleavage product. 529 
Figure Legends

